Theravance Biopharma Inc TBPH 深 沪
已收盘 07-02 16:00:00 美东时间
16.93
-0.050
-0.29%
华盛通- 最 高17.022
- 今 开17.00
- 成交量 161.96万股
- 最 低 16.93
- 昨 收 16.98
- 总市值 8.73亿
- 52周最高 21.03
- 市盈率 静 8.23
- 换手率 3.14%
- 52周最低 10.822
- 委 比 77.64%
- 总股本 5155.30万
- 历史最高 43.44
- 量 比 1.00
- 振 幅 0.54%
- 历史最低 6.10
- 每 手 1
- 风险率 2.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Theravance downgraded at Jones on Zymeworks acquisition
Jones Trading has downgraded Theravance Biopharma (TBPH) to hold from buy following the announcement earlier Monday that Zymeworks (ZYME) is acquiring the company in a $929M deal. Analyst Debanjana Ch...
06-30 02:36
BTIG Downgrades Theravance Biopharma to Neutral
BTIG analyst Julian Harrison downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral.
06-29 23:31
Theravance Biopharma Inc：BTIG将其评级从买入下调至中性
BTIG将生物制药公司Theravance的股票评级从“买入”下调至“中性”。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎。本文由AI大模型基于公...
06-29 21:43
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million. The deal, which aims to bolster Zymeworks’ commercial portfolio, will pay $17 per share for Theravance Biopharma shares. The companies ex...
06-29 21:20
Zymeworks to Acquire Theravance in Strategic Merger
Zymeworks ( ($ZYME) ) has issued an update. On June 28, 2026, Zymeworks Inc. ag...
06-29 19:49
Theravance Biopharma to be Acquired by Zymeworks
The latest update is out from Theravance Biopharma ( ($TBPH) ). Theravance Biop...
06-29 18:59
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure th...
06-29 18:04
Zymeworks将收购Theravance Biopharma, Inc.
核心事件：Zymeworks将收购Theravance Biopharma有限公司。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎。本文由AI大模型...
06-29 18:03
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks Inc. announced its definitive agreement to acquire Theravance Biopharma, Inc. for $17 per share, totaling approximately $929 million. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for COPD, to Zymeworks' portfolio. YUPELRI® generated $266.6 million in U.S. net sales in 2025, with 12% growth over 2024, and $62.4 million in Q1 2026, a 7% increase. The transactio...
06-29 10:00
Theravance Biopharma announces leadership changes amid restructuring
Theravance Biopharma ( ($TBPH) ) just unveiled an announcement. Theravance Biop...
06-24 06:34
